Drugs / Blinatumomab Expanded T-cells (BET)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03823365 | Dec 2018 → Nov 2021 | lymphoid neoplasm | A.O. Ospedale Papa Giovanni XXIII | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Blinatumomab Expanded T-cells (BET) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03823365 ↗ |
| Known as | Blinatumomab-expanded T cells | “Polyclonal T cells can also be expanded in vitro in presence of Blinatumomab and recombinant human IL2 (rhIL2) and have been called BET (Blinatumomab-expanded T cells).” NCT03823365 ↗ |
| Modality | Cell therapy | “Blinatumomab-expanded T cells (BET) are an Advanced Therapeutic Medicinal Product (ATMP) composed of autologous polyclonal activated T cells expanded in vitro using...” NCT03823365 ↗ |